"The discussion highlights a perceived undervaluation of the stock $ATM, drawing comparisons to Biovica, which offers similar tests at a lower price point. Participants express concern over the lack of attention this stock is receiving, suggesting that increased awareness could serve as a catalyst for investment interest."